Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

Pfizer anticipates full-year 2025 revenues to be in the range of $61.0 to $64.0 billion, which includes the expectation of revenues from our COVID-19 products in 2025 being largely consistent with 2024 after excluding approximately $1.2 billion of non-recurring revenue for Paxlovid in 2024. Pfizer expects full-year 2025 operational revenue growth, year-over-year, in a range of approximately flat to 5% from the midpoint of 2024 baseline guidance, which excludes 2024 non-recurring items.

Latest News

12-17

Pfizer Stock Rises After Reassuring 2025 Guidance -- WSJ

12-17

Pfizer Shares up 3.2% After 2025 Profit Forecast

12-17

Pfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion -- Barrons.com

User Discussion

DARKSAMARU

12-17

$Pfizer(PFE)$ 🤔

Pfizer Forecasts in Line 2025 Profit as It Seeks Turnaround

{"i18n":{"language":"en_US"},"financialEventData":{"themeId":"82d36a84b850c4ce90d704ad5a74f9ba","name":"Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance","description":"Pfizer anticipates full-year 2025 revenues to be in the range of $61.0 to $64.0 billion, which includes the expectation of revenues from our COVID-19 products in 2025 being largely consistent with 2024 after excluding approximately $1.2 billion of non-recurring revenue for Paxlovid in 2024. Pfizer expects full-year 2025 operational revenue growth, year-over-year, in a range of approximately flat to 5% from the midpoint of 2024 baseline guidance, which excludes 2024 non-recurring items.","image":"https://community-static.tradeup.com/news/1201dcc0482be040348fb8d4f228bb68","type":2,"style":4,"follow":false,"createTime":1734436526136,"userCounts":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/finance&rndata={\"themeId\":82d36a84b850c4ce90d704ad5a74f9ba}&rnconfig={\"headerBarHidden\": true}","subscribe":false,"allowFollow":false,"hasReward":false,"rewardScore":0,"rewardValidDate":0,"rewardEnd":false,"symbols":["PFE"],"tweetCounts":1,"categoryId":"2929bb7468f5415f853fd96fb35d7c3b","options":[],"votedOptionId":"","totalUserCount":0,"followStatus":false,"themeName":"Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance","tweetAmount":1,"imageIsDefault":true},"news":[{"id":105711,"article_id":"2492966784","title":"Pfizer Stock Rises After Reassuring 2025 Guidance -- WSJ","subtitle":"","subtitle_show":0,"pub_time":1734448080000,"source_id":"dowjones_highlight","language":"en","url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":0,"symbols_score_info":{"PFE":1},"rights":null},{"id":105667,"article_id":"2492796330","title":"Pfizer Shares up 3.2% After 2025 Profit Forecast","subtitle":"","subtitle_show":0,"pub_time":1734445863000,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nL4N3NI108:1","is_publish_highlight":0,"symbols_score_info":{"PFE":0.9},"rights":null},{"id":105591,"article_id":"2492956738","title":"Pfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion -- Barrons.com","subtitle":"","subtitle_show":0,"pub_time":1734438000000,"source_id":"dowjones_highlight","language":"en","url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":0,"symbols_score_info":{"PFE":1},"rights":null},{"id":105590,"article_id":"2492857956","title":"Pfizer Reaffirms Full Year 2024 Guidance and Offers 2025 Earnings, Revenue Outlook","subtitle":"","subtitle_show":0,"pub_time":1734437391000,"source_id":"mtnewswires_news","language":"en","url":"https://www.mtnewswires.com/","is_publish_highlight":0,"symbols_score_info":{"PFE":1},"rights":null},{"id":105588,"article_id":"1155992038","title":"Pfizer Forecasts in Line 2025 Profit as It Seeks Turnaround","subtitle":"","subtitle_show":0,"pub_time":1734436157375,"source_id":"","language":"en","url":"","is_publish_highlight":1,"symbols_score_info":{"PFE":1.1},"rights":null},{"id":105576,"article_id":"2492953876","title":"Pfizer Shares up 3.4% Premarket After 2025 Profit Forecast","subtitle":"","subtitle_show":0,"pub_time":1734436130470,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nFWN3NI0K2:1","is_publish_highlight":0,"symbols_score_info":{"PFE":0.9},"rights":null},{"id":105577,"article_id":"2492953861","title":"Pfizer forecasts 2025 profit in line with expectations","subtitle":"","subtitle_show":0,"pub_time":1734436014000,"source_id":"reuters_news_en","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nL4N3NI0RY:1","is_publish_highlight":0,"symbols_score_info":{"PFE":0.9},"rights":null},{"id":105575,"article_id":"2492538309","title":"Pfizer: Full-Year 2025 Revenue Guidance( Range of $61.0 to $64.0 Bln","subtitle":"","subtitle_show":0,"pub_time":1734435900685,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA2RMSKT:3","is_publish_highlight":0,"symbols_score_info":{"PFE":0.9},"rights":null},{"id":105579,"article_id":"2492953887","title":"Pfizer Inc - 2025 Adjusted Diluted EPS Guidance Range of $2.80 to $3.00","subtitle":"","subtitle_show":0,"pub_time":1734435900685,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA2RMSKT:4","is_publish_highlight":0,"symbols_score_info":{"PFE":0.9},"rights":null},{"id":105578,"article_id":"2492953868","title":"Pfizer: During 2024, Pfizer Recognized Paxlovid Revenue of $1.2 Bln From Two One-Time Items","subtitle":"","subtitle_show":0,"pub_time":1734435900685,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA2RMSKT:8","is_publish_highlight":0,"symbols_score_info":{"PFE":0.9},"rights":null},{"id":105581,"article_id":"2492953858","title":"Pfizer Inc  FY2025 Shr View $2.88, REV View $63.25 Bln -- Lseg Ibes Data","subtitle":"","subtitle_show":0,"pub_time":1734435900685,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA2RMSKT:6","is_publish_highlight":0,"symbols_score_info":{"PFE":0.9},"rights":null},{"id":105580,"article_id":"2492953833","title":"Pfizer - Anticipate an Additional $500 Mln in Savings in 2025 From Ongoing Cost Realignment Program","subtitle":"","subtitle_show":0,"pub_time":1734435900685,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA2RMSKT:5","is_publish_highlight":0,"symbols_score_info":{"PFE":0.9},"rights":null},{"id":105574,"article_id":"2492831953","title":"Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance","subtitle":"","subtitle_show":0,"pub_time":1734435900685,"source_id":"reuters_en_live","language":"en","url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA2RMSKT:1","is_publish_highlight":0,"symbols_score_info":{"PFE":0.9},"rights":null},{"id":105572,"article_id":"2492953852","title":"Press Release: Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance","subtitle":"","subtitle_show":0,"pub_time":1734435900000,"source_id":"dowjones_highlight","language":"en","url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":0,"symbols_score_info":{},"rights":null}],"views":[],"tweetList":[{"id":382579663761728,"gmtCreate":1734438248724,"gmtModify":1734438251350,"author":{"id":"3586214032719642","authorId":"3586214032719642","name":"DARKSAMARU","avatar":"https://static.tigerbbs.com/9a731acebf737eb5a4a29e88be9f5996","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586214032719642","authorIdStr":"3586214032719642"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$&nbsp;</a> 🤔","listText":"<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$&nbsp;</a> 🤔","text":"$Pfizer(PFE)$ 🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382579663761728","repostId":"1155992038","repostType":4,"repost":{"id":"1155992038","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1734436157,"share":"https://ttm.financial/m/news/1155992038?lang=&edition=fundamental","pubTime":"2024-12-17 19:49","market":"us","language":"en","title":"Pfizer Forecasts in Line 2025 Profit as It Seeks Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=1155992038","media":"Reuters","summary":"Dec 17 (Reuters) - Pfizer on Tuesday forecast 2025 profits roughly in line with Wall Street expectations, offering some relief to investors after a tumultuous year during which it attracted criticism ","content":"<html><head></head><body><p>Dec 17 (Reuters) - Pfizer on Tuesday forecast 2025 profits roughly in line with Wall Street expectations, offering some relief to investors after a tumultuous year during which it attracted criticism from activist hedge fund Starboard Value.</p><p>Shares of Pfizer rose about 3% in premarket trading after the drugmaker also said it was expecting 2025 sales of its COVID-19 vaccine and drug to be consistent with 2024 levels.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/9e879631baf8d52ebc58c9c881f82a7a\" title=\"\" tg-width=\"877\" tg-height=\"623\"/></p><p>The company expects adjusted profit of $2.80 to $3 per share, compared with analysts&#39; average estimate of $2.88 per share, according to data compiled by LSEG.</p><p>Pfizer has been reining in costs and shedding non-core businesses to pay down debt as it rebuilds itself after a sharp slump in sales of COVID-19 products.</p><p>Its shares have fallen nearly 12% this year and trade at less than half their value during the peak of the COVID-19 pandemic.</p><p>That has left it open to investor criticism, with Starboard in October saying that Pfizer&#39;s management has over-spent on big acquisitions and failed to produce profitable new drugs from those deals or from its internal research and development.</p><p>&#34;While we see several assets in Pfizer&#39;s pipeline (particularly in oncology) that could make the story more interesting, we believe that further advancement ... will be necessary to change the current narrative on shares which would primarily occur 2026+,&#34; JP Morgan analyst Chris Schott wrote in a research note.</p><p>Pfizer forecast 2025 revenue in the range of $61 billion to $64 billion, compared with the estimates of $63.26 billion.</p><p>The company also estimated a roughly $1 billion hit to its revenue from changes to Medicare&#39;s Part D prescription program under President Biden&#39;s Inflation Reduction Act.</p><p>Pfizer said the addition of new manufacturer discounts and other changes would more than offset expected benefits from the $2,000 out-of-pocket spending cap that will be introduced for seniors who have the prescription drug plan next year.</p><p>The company is slated to hold a conference call with analysts later in the day to discuss the forecast.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Forecasts in Line 2025 Profit as It Seeks Turnaround</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Forecasts in Line 2025 Profit as It Seeks Turnaround\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-12-17 19:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Dec 17 (Reuters) - Pfizer on Tuesday forecast 2025 profits roughly in line with Wall Street expectations, offering some relief to investors after a tumultuous year during which it attracted criticism from activist hedge fund Starboard Value.</p><p>Shares of Pfizer rose about 3% in premarket trading after the drugmaker also said it was expecting 2025 sales of its COVID-19 vaccine and drug to be consistent with 2024 levels.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/9e879631baf8d52ebc58c9c881f82a7a\" title=\"\" tg-width=\"877\" tg-height=\"623\"/></p><p>The company expects adjusted profit of $2.80 to $3 per share, compared with analysts&#39; average estimate of $2.88 per share, according to data compiled by LSEG.</p><p>Pfizer has been reining in costs and shedding non-core businesses to pay down debt as it rebuilds itself after a sharp slump in sales of COVID-19 products.</p><p>Its shares have fallen nearly 12% this year and trade at less than half their value during the peak of the COVID-19 pandemic.</p><p>That has left it open to investor criticism, with Starboard in October saying that Pfizer&#39;s management has over-spent on big acquisitions and failed to produce profitable new drugs from those deals or from its internal research and development.</p><p>&#34;While we see several assets in Pfizer&#39;s pipeline (particularly in oncology) that could make the story more interesting, we believe that further advancement ... will be necessary to change the current narrative on shares which would primarily occur 2026+,&#34; JP Morgan analyst Chris Schott wrote in a research note.</p><p>Pfizer forecast 2025 revenue in the range of $61 billion to $64 billion, compared with the estimates of $63.26 billion.</p><p>The company also estimated a roughly $1 billion hit to its revenue from changes to Medicare&#39;s Part D prescription program under President Biden&#39;s Inflation Reduction Act.</p><p>Pfizer said the addition of new manufacturer discounts and other changes would more than offset expected benefits from the $2,000 out-of-pocket spending cap that will be introduced for seniors who have the prescription drug plan next year.</p><p>The company is slated to hold a conference call with analysts later in the day to discuss the forecast.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155992038","content_text":"Dec 17 (Reuters) - Pfizer on Tuesday forecast 2025 profits roughly in line with Wall Street expectations, offering some relief to investors after a tumultuous year during which it attracted criticism from activist hedge fund Starboard Value.Shares of Pfizer rose about 3% in premarket trading after the drugmaker also said it was expecting 2025 sales of its COVID-19 vaccine and drug to be consistent with 2024 levels.The company expects adjusted profit of $2.80 to $3 per share, compared with analysts' average estimate of $2.88 per share, according to data compiled by LSEG.Pfizer has been reining in costs and shedding non-core businesses to pay down debt as it rebuilds itself after a sharp slump in sales of COVID-19 products.Its shares have fallen nearly 12% this year and trade at less than half their value during the peak of the COVID-19 pandemic.That has left it open to investor criticism, with Starboard in October saying that Pfizer's management has over-spent on big acquisitions and failed to produce profitable new drugs from those deals or from its internal research and development.\"While we see several assets in Pfizer's pipeline (particularly in oncology) that could make the story more interesting, we believe that further advancement ... will be necessary to change the current narrative on shares which would primarily occur 2026+,\" JP Morgan analyst Chris Schott wrote in a research note.Pfizer forecast 2025 revenue in the range of $61 billion to $64 billion, compared with the estimates of $63.26 billion.The company also estimated a roughly $1 billion hit to its revenue from changes to Medicare's Part D prescription program under President Biden's Inflation Reduction Act.Pfizer said the addition of new manufacturer discounts and other changes would more than offset expected benefits from the $2,000 out-of-pocket spending cap that will be introduced for seniors who have the prescription drug plan next year.The company is slated to hold a conference call with analysts later in the day to discuss the forecast.","news_type":1},"isVote":1,"tweetType":1,"viewCount":64,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}]}